comparemela.com

Latest Breaking News On - Prnewswire relmada therapeutics inc - Page 1 : comparemela.com

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

CORAL GABLES, Fla., May 6, 2024 /PRNewswire/ Relmada Therapeutics, Inc. , a late-stage biotechnology company addressing diseases of the central nervous system , today announced that it will.

Tim mccarthyPrnewswire relmada therapeutics incCorporate communicationsRelmada therapeutics incSecurities exchangeConference callRelmada therapeuticsPrivate securities litigation reform actSecurities actSecurities exchange act

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024

CORAL GABLES, Fla., March 12, 2024 /PRNewswire/ Relmada Therapeutics, Inc. , a late-stage biotechnology company addressing diseases of the central nervous system , today announced that it will.

Tim mccarthyPrnewswire relmada therapeutics incRelmada therapeutics incSecurities exchangeCorporate communicationsConference callRelmada therapeuticsPrivate securities litigation reform actSecurities actSecurities exchange act

Relmada Therapeutics Provides Corporate Update

Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated Relmada s Strong Balance Sheet to Support the Company Through All of 2024 s Expected Critical.

Tim mccarthyCedric ogormanSergio traversaPrnewswire relmada therapeutics incCorporate communicationsSecurities exchangeKey clinical development milestonesAndrew cutler as senior clinical development advisorRelmada therapeutics incCompany well positionedMultiple key clinical development milestonesStrong balance sheetCompany through allChief executiveChief medical officerCedrico gorman

Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

Tim mccarthyPrnewswire relmada therapeutics incSecurities exchangeClinical research programRelmada therapeutics incConference callRelmada therapeuticsPrivate securities litigation reform actSecurities actSecurities exchange actHealth care amp hospitalsMedical pharmaceuticalsConference call announcements

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

Comunidad autonoma de catalunaTim mccarthySecurities exchangeClinical research programRelmada therapeutics incEuropean college of neuropsychopharmacologyPrnewswire relmada therapeutics incEuropean collegeRelmada therapeuticsPrivate securities litigation reform actSecurities actSecurities exchange actHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveriesTrade show news

vimarsana © 2020. All Rights Reserved.